Is it necessary to delay antiviral therapy for 3-6 months to anticipate HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B in endemic areas of HBV genotype C?

類似資料

• Correlations of HBV Genotypes, Mutations Affecting HBeAg Expression and HBeAg/ anti-HBe Status in HBV Carriers
  著者:: Lim, Chee Kent, 等
  出版事項: (2006)
• Relative predictive factors for hepatocellular carcinoma after HBeAg seroconversion in HBV infection
  著者:: Murata, Kazumoto, 等
  出版事項: (2005)
• Precore Stop Mutant in HBeAg-Positive Patients with Chronic Hepatitis B: Clinical Characteristics and Correlation with the Course of HBeAg-to-Anti-HBe Seroconversion
  著者:: Chu, Chia-Ming, 等
  出版事項: (2002)
• HBsAg as an important predictor of HBeAg seroconversion following antiviral treatment for HBeAg-positive chronic hepatitis B patients
  著者:: Yang, Jiezuan, 等
  出版事項: (2014)
• Serum Interleukin-37 Concentrations and HBeAg Seroconversion in Chronic HBV Patients During Telbivudine Treatment
  著者:: Li, Cong, 等
  出版事項: (2013)